Correlation Between Seres Therapeutics and Immunitybio

Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and Immunitybio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and Immunitybio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Seres Therapeutics and Immunitybio, you can compare the effects of market volatilities on Seres Therapeutics and Immunitybio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of Immunitybio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and Immunitybio.

Diversification Opportunities for Seres Therapeutics and Immunitybio

-0.03

Correlation Coefficient

Seres Therapeutics  Immunitybio

Good diversification

The 3 months correlation between Seres and Immunitybio is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and Immunitybio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunitybio and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with Immunitybio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunitybio has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and Immunitybio go up and down completely randomly.

Pair Corralation between Seres Therapeutics and Immunitybio

Given the investment horizon of 90 days Seres Therapeutics is expected to under-perform the Immunitybio. But the stock apears to be less risky and, when comparing its historical volatility, Seres Therapeutics is 1.33 times less risky than Immunitybio. The stock trades about -0.02 of its potential returns per unit of risk. The Immunitybio is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  268.00  in Immunitybio on December 30, 2024 and sell it today you would earn a total of  46.00  from holding Immunitybio or generate 17.16% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Seres Therapeutics  vs.  Immunitybio

Seres Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Seres Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Immunitybio

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Immunitybio are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Immunitybio showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Seres Therapeutics and Immunitybio

The main advantage of trading using opposite Seres Therapeutics and Immunitybio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, Immunitybio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunitybio will offset losses from the drop in Immunitybio's long position.

The idea behind Seres Therapeutics and Immunitybio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.